Renovorx Inc (RNXT)

$1.18 +0.03 (2.61%)
Market Cap 42.14M
Revenue (ttm) 40,000.00
Net Income (ttm) -8.81M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,025.00%
Debt to Equity Ratio 0.00
Volume 155,200
Avg Vol 632,704
Day's Range N/A - N/A
Shares Out 36.65M
Stochastic %K 50%
Beta 1.30
Analysts Strong Sell
Price Target $5.62

Company Profile

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.

Industry: Biotechnology
Sector: Healthcare
Phone: 650 284 4433
Fax: 650 397 4433
Address:
2570 West El Camino Real, Suite 320, Mountain View, United States
JackAnalyst
JackAnalyst Oct. 24 at 2:42 PM
Friday check , $RNXT holding $1.17, green week so far. That $1.15 base holding strong. Waiting on the next catalyst.
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 23 at 7:05 PM
$RNXT reached an important line first patient treated with its patented, FDA-cleared RenovoCath®️. bigger updates likely next.. any thoughts?
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 22 at 9:27 PM
$RNXT Only big news coming here is a Sheeny man reverse split.
0 · Reply
JackAnalyst
JackAnalyst Oct. 22 at 8:35 PM
NK cell therapies are changing the game $254B market ahead. $RNXT’s precision delivery fits right into that future. Could 2026 be the year this story starts to move?
1 · Reply
NAKAttac
NAKAttac Oct. 22 at 5:47 PM
$RNXT Some big news coming at this end of the week!
1 · Reply
Wolfietrader
Wolfietrader Oct. 21 at 4:48 PM
$RNXT this stock cannot figure what to do.
0 · Reply
JackAnalyst
JackAnalyst Oct. 20 at 6:23 PM
Strong Monday open for $RNXT Sitting around $1.17 (+4.5%) by mid-day with steady volume.Feels like buyers are creeping back in after last week’s lull. Watching to see if it can build above $1.20 this week
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:51 PM
$RNXT has FDA cleared RenovoCath already generating revenue, TAMP technology used in solid tumors targets medicine where it needs to be instead of systemic poisoning with ugly side effects. TigerPac pancreatic in phase III, 2 interim look showed a 6 month survival advance, DSMB recommended trial to continue. 65% reduction in Adverse events compared to standard of care.
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:43 PM
$RNXT the sleeping giant.
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Oct. 20 at 3:12 PM
$RNXT let’s break out of this channel
0 · Reply
Latest News on RNXT
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

Oct 9, 2025, 8:30 AM EDT - 16 days ago

RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

Sep 25, 2025, 8:30 AM EDT - 4 weeks ago

RenovoRx's PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

Sep 11, 2025, 8:30 AM EDT - 6 weeks ago

RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

Aug 20, 2025, 8:30 AM EDT - 2 months ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

Aug 14, 2025, 4:05 PM EDT - 2 months ago

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

Aug 6, 2025, 8:30 AM EDT - 2 months ago

RenovoRx Expands U.S. Commercialization Efforts for the RenovoCath® Device with Growing Customer Demand and Key Leadership Hire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

Jul 28, 2025, 8:30 AM EDT - 3 months ago

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

Jul 14, 2025, 8:30 AM EDT - 3 months ago

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 9:07 PM EDT - 5 months ago

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025, 4:05 PM EDT - 5 months ago

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025, 8:30 AM EDT - 5 months ago

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025, 8:30 AM EDT - 6 months ago

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

May 1, 2025, 8:30 AM EDT - 6 months ago

RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

Apr 29, 2025, 8:30 AM EDT - 6 months ago

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx's Ongoing Phase III TIGeR-PaC Clinical Trial

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

Apr 16, 2025, 8:30 AM EDT - 6 months ago

RenovoRx Increases U.S. Production of RenovoCath® Devices to Meet Growing Demand from Oncology Community

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

Apr 4, 2025, 8:30 AM EDT - 7 months ago

RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Apr 1, 2025, 8:30 AM EDT - 7 months ago

RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

Mar 28, 2025, 8:00 AM EDT - 7 months ago

RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

Mar 26, 2025, 8:00 AM EDT - 7 months ago

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

Mar 20, 2025, 8:00 AM EDT - 7 months ago

RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

Mar 19, 2025, 8:00 AM EDT - 7 months ago

RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

Feb 26, 2025, 8:00 AM EST - 8 months ago

RenovoRx Advances Commercialization of RenovoCath® with Several New Purchase Orders, Including Customer Reorders

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

Feb 13, 2025, 8:00 AM EST - 9 months ago

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 11, 2025, 7:00 AM EST - 9 months ago

RenovoRx Announces Closing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

Feb 6, 2025, 8:49 PM EST - 9 months ago

RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock

RenovoRx Announces Proposed Public Offering

Feb 6, 2025, 4:05 PM EST - 9 months ago

RenovoRx Announces Proposed Public Offering

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

Feb 5, 2025, 2:14 AM EST - 9 months ago

RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

Jan 27, 2025, 8:00 AM EST - 9 months ago

RenovoRx Highlights Promising Pharmacokinetic Data Abstract Presented at ASCO GI 2025

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

Jan 8, 2025, 8:00 AM EST - 10 months ago

RenovoRx Announces Acceptance of Abstract for Presentation at ASCO Gastrointestinal Cancers Symposium 2025

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Dec 30, 2024, 8:00 AM EST - 10 months ago

RenovoRx Continues to Grow Intellectual Property Portfolio for its Novel Drug-Delivery Therapy Platform

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Nov 20, 2024, 8:45 AM EST - 1 year ago

Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx's Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

Sep 25, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

Sep 19, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

Aug 27, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

Aug 14, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

Jul 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Jun 26, 2024, 8:30 AM EDT - 1 year ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

Jun 10, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

RenovoRx CEO Issues Update Letter to Shareholders

May 30, 2024, 8:30 AM EDT - 1 year ago

RenovoRx CEO Issues Update Letter to Shareholders

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

May 21, 2024, 9:00 AM EDT - 1 year ago

Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

May 14, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

May 2, 2024, 9:00 AM EDT - 1 year ago

RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

Apr 18, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Apr 16, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

Apr 15, 2024, 8:00 AM EDT - 1 year ago

RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026

RenovoRx Announces $11.1 Million at Market Private Placement

Apr 8, 2024, 8:30 AM EDT - 1 year ago

RenovoRx Announces $11.1 Million at Market Private Placement

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

Apr 5, 2024, 8:30 AM EDT - 1 year ago

RenovoRx to Present at the Canaccord Genuity Horizons in Oncology Virtual Conference on April 15, 2024

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

Mar 12, 2024, 9:00 AM EDT - 1 year ago

RenovoRx to Present at the 36th Annual ROTH Conference on March 19, 2024

RenovoRx Highlights Key Leadership Promotions

Mar 8, 2024, 4:05 PM EST - 1 year ago

RenovoRx Highlights Key Leadership Promotions

JackAnalyst
JackAnalyst Oct. 24 at 2:42 PM
Friday check , $RNXT holding $1.17, green week so far. That $1.15 base holding strong. Waiting on the next catalyst.
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 23 at 7:05 PM
$RNXT reached an important line first patient treated with its patented, FDA-cleared RenovoCath®️. bigger updates likely next.. any thoughts?
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 22 at 9:27 PM
$RNXT Only big news coming here is a Sheeny man reverse split.
0 · Reply
JackAnalyst
JackAnalyst Oct. 22 at 8:35 PM
NK cell therapies are changing the game $254B market ahead. $RNXT’s precision delivery fits right into that future. Could 2026 be the year this story starts to move?
1 · Reply
NAKAttac
NAKAttac Oct. 22 at 5:47 PM
$RNXT Some big news coming at this end of the week!
1 · Reply
Wolfietrader
Wolfietrader Oct. 21 at 4:48 PM
$RNXT this stock cannot figure what to do.
0 · Reply
JackAnalyst
JackAnalyst Oct. 20 at 6:23 PM
Strong Monday open for $RNXT Sitting around $1.17 (+4.5%) by mid-day with steady volume.Feels like buyers are creeping back in after last week’s lull. Watching to see if it can build above $1.20 this week
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:51 PM
$RNXT has FDA cleared RenovoCath already generating revenue, TAMP technology used in solid tumors targets medicine where it needs to be instead of systemic poisoning with ugly side effects. TigerPac pancreatic in phase III, 2 interim look showed a 6 month survival advance, DSMB recommended trial to continue. 65% reduction in Adverse events compared to standard of care.
0 · Reply
Babyhuey
Babyhuey Oct. 20 at 5:43 PM
$RNXT the sleeping giant.
0 · Reply
TimmyTheSleuth
TimmyTheSleuth Oct. 20 at 3:12 PM
$RNXT let’s break out of this channel
0 · Reply
Luckyluck39
Luckyluck39 Oct. 17 at 1:46 PM
$RNXT waiting for 0.90
0 · Reply
PLX_BULLS
PLX_BULLS Oct. 17 at 3:32 AM
$RNXT When’s the next catalyst?
2 · Reply
Northern_Lightz
Northern_Lightz Oct. 16 at 7:55 PM
What if the next update from $RNXT connects all these dots; platform, advisors, and real data? It would totally change how people view this stock.
0 · Reply
Rnxtsavior
Rnxtsavior Oct. 16 at 2:55 PM
$RNXT Every time they find a new sucker to buy in... Sheeny man sucks it down. So obvious so funny.
1 · Reply
Benjamin47
Benjamin47 Oct. 16 at 9:15 AM
$RNXT Earnings will be out November 13th. >1M revenue is my prediction 🚀
1 · Reply
SocioCobb
SocioCobb Oct. 15 at 11:17 PM
$RNXT 45% return, 3 weeks. God bless the free market!
0 · Reply
Babyhuey
Babyhuey Oct. 15 at 8:40 PM
$RNXT
0 · Reply
NoWeAreNotOkay
NoWeAreNotOkay Oct. 15 at 8:09 PM
$RNXT Great day at RNXT
0 · Reply
Northern_Lightz
Northern_Lightz Oct. 15 at 2:03 PM
Meanwhile $RNXT quietly building its dream team
0 · Reply
CunningStunt69
CunningStunt69 Oct. 14 at 6:58 PM
$RNXT needs about $5 mil a quarter in sales to break even. I do hope they can get there quickly. In the long run if they really can get $400 mil a year in sales they’ll be printing cash.
1 · Reply
Northern_Lightz
Northern_Lightz Oct. 14 at 6:47 PM
$RNXT up again this week. Combine that with two new oncology heavyweights… timing looks interesting.
0 · Reply
Sahil1991
Sahil1991 Oct. 13 at 10:13 PM
$DCTH How does $RNXT compare this story? I looked at $RNXT And liked what I saw, and they seem to be in similar stage (early commercialisation with R&D to broaden indications), sector (oncology), and product (delivery device). They aren’t competing with $DCTH . I invested today…
1 · Reply